


**IsoCyp-Tox** is an innovative cell-based and ready-to-use kit. The kit consists of 96-well plates seeded with the hepatic cell line HepG2 transiently transduced with individual human CYP450 isoforms, making these cells metabolically competent. **IsoCyp-Tox** allows *in vitro* detection and screening of biotransformation mediated-toxicity of lead and drug targets in just one single experiment. **IsoCyp-Tox** is a powerful as well as time and cost-saving tool during hit-to-lead and lead optimization phases in early stage of drug discovery and development.

## IsoCyp-Tox Applications

- Early detection and screening of potential bioactivation-dependent acute toxicity of target compounds
- Identification of CYP isoforms involved in potential production of toxic metabolites
- Metabolic activation screening

## IsoCyp-Tox Features

- Ready-to-use
- Single human CYP450 isoform expression (3A4, 2E1, 1A2, 2A6, 2C9, 2C19)
- High CYP450 isoform activities
- 96-well plate format
- Customizable plate design
- Exclusive solid shipping medium




Wild type hepatic human cell line

## IsoCyp-Tox Benefits

- Suitable to current toxicity end-points (MTT, WST1, LDH, ATP, etc) without specific know-how
- Cost-effective and time saving due to reduction of in-house maintenance and handling of cell cultures
- Identification of specific CYPs involved in potential production of toxic metabolites in just one experiment
- Designed to allow dose-response studies & IC50 curve fitting at early stage
- High reproducibility
- Adaptable to automated procedures and High Throughput Screening
- Available for just-in-time use
- Similar or even higher CYP activity levels than those observed in fresh human hepatocytes
- Shipping medium easily to remove by liquefaction at 37°C

## IsoCyp-Tox Experimental Data: Curve fitting of IC50 values of test compounds



Wild type hepatic human cell line (HepG2) transiently transfected with human CYP450 isoforms 1A2, 2E1, 3A4 and 2A6. For endpoint WST-1 assay, figures show, specific bioactivation in 3A4 and, to a lesser extent, in 1A2 for Aflatoxin B1 (Fig.1); parent compound toxicity for sodium diclofenac (Fig.2) and general toxicity for potassium bromate (nonmediated by CYP450 specific metabolism) (Fig.3)

## FOUR SIMPLE STEPS OF IsoCyp-Tox

**RECEIVE**

Ready-to-use HepG2 transiently transfected cell line

**LIQUIFY**

Liquefying of solid shipping medium at 37°C

**APPLY**

Incubation with test compound

**ASSAY**

Assessment of a simple toxicity endpoint

## Formats

### IsoCyp-Tox standard kit containing 7 x 96-well plates, Ref. KRECE-ICT50:

- 6 x 96-well plates of HepG2 transfected with single CYP450 isoform, including 1 x 96-well plate for each CYP450 isoform (3A4, 2E1, 1A2, 2A6, 2C9 and 2C19)
- 1 x 96-well control plate of HepG2 untransfected (metabolic incompetent cells)

### IsoCyp-Tox individual CYP450 kit containing 2 x 96-well plates:

- 1 x 96-well plate of HepG2 transfected with single CYP450 of interest:  
3A4: Ref. KRECE-ICT51, 2E1: Ref. KRECE-ICT52, 1A2: Ref. KRECE-ICT53, 2A6: Ref. KRECE-ICT54, 2C9: Ref. KRECE-ICT55 or 2C19: Ref. KRECE-ICT56
- 1 x 96-well control plate of HepG2 untransfected (metabolic incompetent cells)